Improvement of glucose metabolism

"Improvement of glucose metabolism" is a broad therapeutic outcome rather than a specific molecular target such as a receptor or enzyme. It refers to the physiological process of restoring or enhancing the body's ability to maintain glucose homeostasis, which is frequently impaired in metabolic diseases like Type 2 Diabetes Mellitus (T2DM), obesity, and metabolic syndrome [1, 4]. This outcome is achieved through various biological mechanisms, including the stimulation of insulin secretion from pancreatic beta cells, the reduction of hepatic glucose production (gluconeogenesis), and the enhancement of insulin sensitivity in peripheral tissues like skeletal muscle and adipose tissue [3, 8]. Numerous pharmacological classes target specific proteins to achieve this goal, such as GLP-1 receptor agonists, SGLT2 inhibitors, and biguanides like metformin [6, 9]. In clinical settings, the efficacy of treatments aimed at improving glucose metabolism is primarily monitored using biomarkers such as HbA1c and fasting blood glucose levels [7]. Because it describes a systemic biological effect rather than a discrete molecule, it is considered a physiological endpoint of multi-target drug action.

Other names

Glucose homeostasisGlycemic controlGlucose regulationGlucose modulationGlucose homeostasis regulation

Improving glucose metabolism is achieved through diverse mechanisms depending on the drug class: 1) Increasing insulin sensitivity in the liver and muscle (e.g., Metformin via AMPK activation [6, 8]); 2) Stimulating glucose-dependent insulin secretion and inhibiting glucagon release (e.g., GLP-1 receptor agonists and DPP-4 inhibitors [3, 5]); 3) Promoting urinary glucose excretion by blocking renal reabsorption (e.g., SGLT2 inhibitors [6]); and 4) Direct activation of insulin receptors through exogenous insulin therapy [7].